Young patients (under 50) undergoing TKA are a growing, high-demand population where implant longevity is a primary concern. This single-institution retrospective study reports midterm survivorship, functional, and radiographic outcomes of newer-generation cementless TKA in 29 patients (31 knees) with mean age 45 and mean follow-up of 4 years.
The core tension in young-patient TKA is durability. Younger patients are more active, place greater stress on implants, and will outlive their prostheses by decades — making fixation strategy a critical decision.
Cemented TKA carries risks of osteolysis and aseptic loosening at the bone-cement interface that are particularly concerning in high-demand patients. Cementless designs with bioactive coatings aim to eliminate that failure mode by achieving direct bone ingrowth.
This study reports reassuring midterm data: 100% survivorship with no complications in patients under 50 at 4 years. However, the critical limitation is that 4 years is insufficient to judge longevity in a patient who may need the implant to last 30-40 years. Cemented TKA has published 10- to 18-year survivorship data (94-98%) that cementless designs have not yet matched in the young cohort.
For boards and clinical practice: the question is not whether cementless TKA works short-term — it does. The unanswered question is whether it outperforms cemented fixation over the long term in patients under 50. That evidence does not yet exist, and this study's authors acknowledge it explicitly.
Young patients (under 50) undergoing TKA are a growing, high-demand population where implant longevity is a primary concern. This single-institution retrospective study reports midterm survivorship, functional, and radiographic outcomes of newer-generation cementless TKA in 29 patients (31 knees) with mean age 45 and mean follow-up of 4 years.
The core tension in young-patient TKA is durability. Younger patients are more active, place greater stress on implants, and will outlive their prostheses by decades — making fixation strategy a critical decision.
Cemented TKA carries risks of osteolysis and aseptic loosening at the bone-cement interface that are particularly concerning in high-demand patients. Cementless designs with bioactive coatings aim to eliminate that failure mode by achieving direct bone ingrowth.
This study reports reassuring midterm data: 100% survivorship with no complications in patients under 50 at 4 years. However, the critical limitation is that 4 years is insufficient to judge longevity in a patient who may need the implant to last 30-40 years. Cemented TKA has published 10- to 18-year survivorship data (94-98%) that cementless designs have not yet matched in the young cohort.
For boards and clinical practice: the question is not whether cementless TKA works short-term — it does. The unanswered question is whether it outperforms cemented fixation over the long term in patients under 50. That evidence does not yet exist, and this study's authors acknowledge it explicitly.